Beti-cel gene therapy achieves high rates of transfusion independence in severe β-thalassemia
1. 89% of patients achieved transfusion independence with beti-cel gene therapy. 2. There were no serious adverse events or treatment-related ...
1. 89% of patients achieved transfusion independence with beti-cel gene therapy. 2. There were no serious adverse events or treatment-related ...
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. 80% of patients receiving mitapivat showed hemoglobin response at 12 weeks. 2. Markers of hemolysis, such as bilirubin and ...
1. Betibeglogene autotemcel (beti-cel) gene therapy resulted in sustained hemoglobin A with a T87Q amino acid substitution (HbAT87Q) in non-β0/β0 ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.